CIM
PTCT icon

Cambria Investment Management’s PTC Therapeutics PTCT Stock Holding History

Cambria Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$930K Buy
11,398
+773
+7% +$55.8K 0.05% 356
2026
Q1 		$724K Buy
10,625
+1,979
+23% +$140K 0.04% 287
2025
Q4 		$657K Sell
8,646
-2,988
-26% -$217K 0.04% 312
2025
Q3 		$714K Buy
11,634
+2,322
+25% +$121K 0.04% 276
2025
Q2 		$455K Buy
+9,312
New +$442K 0.03% 314

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Cambria Investment Management's PTCT Position: Q2 2026 in Review

Cambria Investment Management increased its PTC Therapeutics (PTCT) stake by 7.3% in Q2 2026, buying an estimated $55.8K and bringing the position to 11,398 shares worth $930K. The position accounts for 0.05% of the portfolio, ranked #356.

Cambria Investment Management first reported a position in PTCT in Q2 2025 and has held it in 5 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Cambria Investment Management held 11,398 shares of PTC Therapeutics worth $930K as of Q2 2026.
  • Cambria Investment Management bought 773 PTC Therapeutics shares in Q2 2026, an estimated $55.8K.
  • PTC Therapeutics made up 0.05% of Cambria Investment Management's portfolio in Q2 2026, its #356 holding.
  • Cambria Investment Management first reported a position in PTC Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Cambria Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.